ReviewACS nano2025
Perspective on Nano-Enabled Photostimulation Biointerfaces.
Review in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanostructures enable precise control of biological systems through photoelectrochemical, photothermal, and photocatalytic mechanisms at the cellular and subcellular levels. Here, we discuss three emerging directions in nano-enabled photostimulation biointerfaces. First, artificial intelligence (AI)-driven materials design and high-throughput screening accelerate discovery of optimized nanostructures. Second, innovative device architectures─including robotic assisted and closed-loop platforms─provide real-time monitoring and precise light delivery. Third, expanding applications in tissue engineering and biohybrid systems foster advances in regenerative medicine and neural modulation. By integrating these approaches with nanotechnology, future photostimulation platforms promise highly efficient, customizable, and minimally invasive therapies, offering opportunities in targeted drug delivery, personalized healthcare, and sustainable biomedical technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.